ReviewMolecular medicine reports2025
Mechanisms and interventions in aneurysmal subarachnoid hemorrhage: Unraveling the role of inflammatory responses and cell death in early brain injury (Review).
Review in Molecular medicine reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Subarachnoid hemorrhage: epidemiology, risk factors, pathogenesis, and clinical therapies.Molecular biomedicine · 2026Review
- A narrative review of pathophysiology and therapeutic frontiers in early brain injury followed by aneurysm subarachnoid hemorrhage.Surgical neurology international · 2026Review
- Systemic inflammation response index as an independent predictor of unfavorable prognosis and its application in risk stratification in patients with aneurysmal subarachnoid hemorrhage.Frontiers in neuroscience · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aneurysmal subarachnoid hemorrhage (aSAH) is a subtype of stroke associated with high morbidity and mortality rates worldwide, posing challenges in developing effective treatment strategies. The present review aimed to summarize the role of inflammation and pyroptosis in early brain injury (EBI), a key determinant of outcomes in aSAH, the interplay between oxidative stress, neuroinflammation and cell death and the immune‑inflammatory response and oxidative stress as central components in the pathogenesis of aSAH. Key signaling pathways include toll‑like receptor 4/NF‑κB and NLR family pyrin domain‑containing 3/gasdermin D pathways, which regulate inflammatory responses and pyroptotic cell death. Additionally, current and traditional Chinese therapeutic approaches to mitigating EBI and improving patient outcomes are summarized, demonstrating the potential roles of salvianolic acid B, pterostilbene, luteolin and electro‑acupuncture. The findings of the present review underscore the necessity for continued research into the molecular mechanisms underlying aSAH to translate these insights into clinical practice, enhancing patient survival and recovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.